Bomedemstat ditosylate

• CAT Number: I023610
• CAS Number: 1990504-72-7
• Molecular Formula: C42H50FN7O8S2
• Molecular Weight: 864.02
• Purity: 98%
• Solubility: Soluble in DMSO
• Storage: 4°C, away from moisture
• IUPAC Name: N-((2S)-5-(((1R,2S)-2-(4-Fluorophenyl)cyclopropyl)amino)-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl)-4-(1H-1,2,3-triazol-1-yl)benzamide bis-tosylate salt
• InChI: InChI=1S/C28H34FN7O2.2C7H8O3S/c1-34-15-17-35(18-16-34)28(38)25(3-2-12-30-26-19-24(26)20-4-8-22(29)9-5-20)32-27(37)21-6-10-23(11-7-21)36-14-13-31-33-36;2*1-6-2-4-7(5-3-6)11(8,9)10/h4-11,13-14,24-26,30H,2-3,12,15-19H2,1H3,(H,32,37);2*2-5H,1H3,(H,8,9,10)/t24-,25-,26+;;/m0../s1
• InChIKey: WLRWBXFBIJMKHG-DVNXTAPYSA-N
• SMILES: O=C(N[C@@H](CCCN[C@H]1[C@H](C2=CC=C(F)C=C2)C1)C(N3CCN(C)CC3)=O)C4=CC=C(N5N=NC=C5)C=C4.OS(=O)(C6=CC=C(C)C=C6)=O.OS(=O)(C7=CC=C(C)C=C7)=O

Bomedemstat（Cat No.:I023610）, also referred to as IMG-7289, is an inhibitor of lysine-specific histone demethylase 1 (LSD1) with potential antineoplastic activity. It shows promise in the treatment of conditions such as acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis. Bomedemstat selectively inhibits the proliferation of JAK2 V617F cells, inducing apoptosis. It achieves this by increasing the expression and methylation of p53, along with the pro-apoptotic factor PUMA, while reducing the levels of the antiapoptotic antagonist BCLXL.

Reference

1: Fu X, Zhang P, Yu B. Advances toward LSD1 inhibitors for cancer therapy. Future Med Chem. 2017 Jul;9(11):1227-1242. doi: 10.4155/fmc-2017-0068. Epub 2017 Jul 19. Review. PubMed PMID: 28722477.
2: Jutzi JS, Kleppe M, Dias J, Staehle HF, Shank K, Teruya-Feldstein J, Gambheer SMM, Dierks C, Rienhoff HY Jr, Levine RL, Pahl HL. LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone. Hemasphere. 2018 Jun 8;2(3):e54. doi: 10.1097/HS9.0000000000000054. eCollection 2018 Jun. PubMed PMID: 31723778; PubMed Central PMCID: PMC6745991.
3: Fang Y, Liao G, Yu B. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019 Dec 4;12(1):129. doi: 10.1186/s13045-019-0811-9. Review. PubMed PMID: 31801559; PubMed Central PMCID: PMC6894138.